Elahere shows midstage success in ovarian cancer subtype after AbbVie's ImmunoGen acquisition

AbbVie, a prominent player in the pharmaceutical industry, has made significant strides in the field of antibody-drug conjugates (ADCs) following its $10.1 billion acquisition of ImmunoGen. This strategic buyout has yielded notable outcomes, particularly with the inherited commercial therapy, Elahere, also known as mirvetuximab soravtansine.

Elahere, which targets folate receptor-alpha (FRa) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults, had previously received full approval from the FDA in March 2023, following an initial accelerated approval in November 2022. The drug is intended for patients who have undergone up to three prior treatments.

In a recent midstage PICCOLO trial, Elahere achieved its primary endpoint, recording an objective response rate (ORR) of 51.9%. Although AbbVie did not disclose whether the secondary endpoint was fully met, the median duration of response (DOR) for Elahere was reported to be 8.25 months. The phase 2 study focused on the use of Elahere as a monotherapy in patients with heavily pretreated, FRa-positive, platinum-sensitive ovarian cancer (PSOC).

AbbVie defines platinum-sensitive patients as those who initially responded to platinum-based chemotherapy and then relapsed six months or more after the initial treatment. Conversely, platinum-resistant patients are those who experience a relapse within six months after undergoing platinum-based chemotherapy.

In terms of safety, Elahere's profile was consistent with previous studies, with no new safety concerns emerging. Detailed results from the midstage trial are yet to be fully disclosed, but AbbVie plans to present the data at a future medical conference.

The acquisition of ImmunoGen, according to AbbVie CEO Rick Gonzalez, was a strategic move intended to bolster AbbVie's presence in the solid tumor market and enhance its oncology pipeline. The company aims to position Elahere in earlier lines of treatment and is also exploring the potential of combining Elahere with Roche’s Avastin (bevacizumab) or PARP inhibitors for first-line maintenance therapy. Phase 3 studies for these combinations are anticipated to commence in 2024 and 2025.

AbbVie's foray into the ADC sector aligns it with other major pharmaceutical companies that are investing in this innovative field, including AstraZeneca, BioNTech, Gilead Sciences, GSK, Merck & Co., and Pfizer. This move is part of a broader trend where big pharma companies are increasingly turning to ADCs to enhance their cancer treatment portfolios.

Recent notable investments in the ADC field include Pfizer's $43 billion acquisition of ADC leader Seagen and Merck's $10.8 billion purchase of immunology company Prometheus. These acquisitions reflect a growing industry confidence in the potential of ADCs to revolutionize cancer treatment.

In summary, AbbVie's strategic acquisition of ImmunoGen has already demonstrated promising results with Elahere's clinical performance. The company’s efforts to expand Elahere's use in earlier lines of treatment and explore combination therapies signify a robust commitment to advancing its oncology offerings and maintaining its competitive edge in the rapidly evolving pharmaceutical landscape.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!